Request more information about PERTZYE® (pancrelipase)

If you would like to learn more about PERTZYE, get updates when they become available, or have one of our sales representatives contact you, please fill out the fields below.


I am interested in:

Additional information about PERTZYE as it becomes available

Communication from a Chiesi sales representative

PERTZYE samples

All fields are required.

Occupation

Title

First Name

Last Name

Email Address

By checking this box, you are giving Chiesi, Inc. permission to send or contact you with the information you have requested, as well as information and updates on PERTZYE® (pancrelipase) or other Chiesi products in the future. Chiesi, Inc. will not sell or share any of your information with third parties.



Additional information about PERTZYE as it becomes available

Communication from a Chiesi sales representative

PERTZYE samples

All fields are required.

Occupation

Title

First Name

Last Name

Email Address

Address

Address 2 (optional)

City

ZIP Code

Phone Number

State

By checking this box, you are giving Chiesi, Inc. permission to send or contact you with the information you have requested, as well as information and updates on PERTZYE® (pancrelipase) or other Chiesi products in the future. Chiesi, Inc. will not sell or share any of your information with third parties.

Yes, I accept the terms and conditions above

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.

Indication

PERTZYE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Please click here for Full Prescribing Information and Medication Guide.